Response Versus Remission in Obsessive-Compulsive Disorder
The DOI matches its Crossref record.
Abstract
Article Abstract Objective: To investigate rates of response and remission in adults with obsessive-compulsive disorder (OCD) after 12 weeks of evidence-based treatment. Method: Post hoc analyses of response and remission were conducted using data from a multisite, randomized, controlled trial comparing the effects of 12 weeks of exposure and ritual prevention (EX/RP), clomipramine (CMI), their combination (EX/RP+CMI), or pill placebo (PBO) in 122 adults with OCD (DSM-III-R or DSM-IV criteria). Response was defined as a decrease in symptoms; remission was defined as minimal symptoms after treatment. Different response and remission definitions were constructed based on criteria used in prior studies. For each definition, the proportion of responders or remitters in each treatment group was then compared. Results: There were significant differences (p < .05) among the 4 treatment groups in the proportion of responders and remitters. In pairwise comparisons, EX/RP + CMI and EX/RP each produced significantly more responders and remitters than PBO; CMI produced significantly more responders and remitters than PBO for some definitions but not for others. When remission was defined as a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of 12 or less, significantly more EX/RP + CMI (18/31 ) and EX/RP (15/29 ) patients entering treatment achieved remission than either CMI (9/36 ) or PBO (0/26 ) patients. However, even in treatment completers, many CMI and some EX/RP + CMI and EX/RP patients did not achieve remission (remission rates for YBOCS < = 12: EX/RP + CMI = 13/19 ; EX/RP = 15/21 ; CMI = 8/27 ; PBO = 0/20 ). Conclusion: EX/RP (with or without CMI) can lead to superior treatment outcome compared with CMI alone in OCD patients without comorbid depression. However, many OCD patients who receive evidence-based treatment do not achieve remission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“exposure and response prevention (ERP), which is now considered to be the first-line psychotherapy for the disorder.”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [26]
In the citing paper
“only about half of the patients who receive it will reach complete symptom remission.[26]”
From Exposure and response prevention for obsessive-compulsive disorder: A review and new directions (2019) · cites this paper as [26]
In the citing paper
“EX/RP typically helps up to half of patients achieve minimal symptoms after treatment (i.e., remission) (12).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
In the citing paper
“this cutoff not only reflects minimal symptoms after treatment but also predicts good quality of life and adaptive functioning (12,26,30).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
In the citing paper
“operationalized as a posttreatment Y-BOCS score ≤ 12, given that this cutoff reflects symptom reduction and predicts good quality of life and adaptive functioning (12,26,30).”
From Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder (2019) · cites this paper as [12]
Citations
Cited by
Items 201–239 of 239
"Functional," Sub-Clinical Obsessive-Compulsive Symptoms and Their Challenges: The Case of "Angela"
Pontes, L. M., & Pereira, R. F. (2013) · Pragmatic Case Studies in Psychotherapy · doi:10.14713/pcsp.v9i1.1806 · Cited by 1
Voderholzer, U. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_70 · Cited by 1
Progress in Neurotherapeutics and Neuropsychopharmacology 2007
Cummings, J. L. (2006) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232106000024 · Cited by 1
Maataoui, Z. E., Belhadga, H., & Kisra, H. (2023) · Scholars Academic Journal of Biosciences · doi:10.36347/sajb.2023.v11i10.008 · Cited by 1
Universidad Católica Santiago de Guayaquil, G., Vivanco, R. A., Rech, L., Ramos-Orosco, E. J., Prilip, P., Mengide, J. P., Rivera, P. B., Vargas-Ruiz, A., Barros, L. C. M., Abbarh, S., et al. (2024) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2023.94.4 · Cited by 1
Kapfhammer, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_58 · Cited by 1
Methodological Issues for Clinical Treatment Trials in Obsessive‐Compulsive Disorder
Reghunandanan, S., & Fineberg, N. A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch8 · Cited by 1
Simpson, H. B., & Harrison-Read, P. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.037 · Cited by 1
Self-citationSelles, R. R. (2013) · Digital Commons - University of South Florida (University of South Florida) · Cited by 1
Costa, D. L. D. C. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-05122016-164417 · Cited by 2
Costs and benefits of neuroimaging research in obsessive-compulsive disorder: time to take stock
Grant, J. E., & Chamberlain, S. R. (2018) · CNS Spectrums · doi:10.1017/s1092852918000901 · Cited by 1
“With prompt evidence-based intervention, 60–65% of affected individuals experience symptom reduction and up to 40–50% experience remission.(2) The American Psychiatric Association (USA) and the National Institute for Health and Care Excellence (UK) have published guidelines regarding the diagnosis and management of OC…”
BackgroundThe Treatment of Obsessive-Compulsive Disorder
Collins, L. M., Bragdon, L. B., & Coles, M. E. (2018) · Evidence‐Based Psychotherapy · doi:10.1002/9781119462996.ch6 · Cited by 1
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors
Schneier, F. R. (2012) · Wiley eBooks · doi:10.1002/9781119945901.ch3
Progress in Neurotherapeutics and Neuropsychopharmacology 2008
Cummings, J. L. (2008) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232107000183
[Therapeutic strategies for obsessive-compulsive disorder refractory to treatment].
Mussa, A. (2008) · PubMed · Cited by 1
Integrative Therapie der Zwangsstörungen
Voderholzer, U. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_70-1
“Simpson et al. (2006) ergänzten die Daten von Foa et al. und zeigten, dass bei strengen Remissionskriterien 8 % der Patienten aus der Clomipramin-Gruppe und 35 % der Patienten aus der Kombinationsgruppe vollständig remittierten.”
BackgroundObsessive Compulsive Disorder: Cognitive Behavioral Therapy via Exposure and Response Prevention
Augustin, D. (2012) · NSUWorks (Nova Southeastern University)
Terapia de Aceptación y Compromiso como Tratamiento de Elección para el TOC: un Estudio de Caso
de la Torre‐Luque, A., & Aguayo, L. V. (2017) · Revista de Psicoterapia · doi:10.33898/rdp.v28i106.150
Rubio, C. R. G. (2017) · Gredos (University of Salamanca) · doi:10.14201/gredos.136274 · Cited by 1
Stovezky, Y. R., Gershkovich, M., Kayser, R. R., & Simpson, H. (2019) · A Transdiagnostic Approach to Obsessions, Compulsions and Related Phenomena · doi:10.1017/9781108164313.020
Self-citationTorkamani, F., Nazaraghaie, F., & Nami, M. (2019) · NeuroQuantology · doi:10.14704/nq.2019.17.8.2019 · Cited by 3
“Meanwhile, up to one third of patients are found be refractory to ERPbased CBT or medication therapy (Kozak et al., 2000; Simpson et al., 2006).”
BackgroundAchtsamkeitsbasierte Interventionen bei Zwängen
Külz, A. K. (2020) · Psychotherapie: Praxis · doi:10.1007/978-3-662-60318-5_5
PhD, P. S. (2008) · Wiley eBooks · doi:10.1002/9780470773192.refs
Combining Pharmacotherapy and Psychological Treatments for Obsessive-Compulsive Disorder
Tolin, D. F., & Sain, K. S. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190068752.013.21
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Self-citationChapter 24. Obsessive-Compulsive Disorder
Das, B., & Koran, L. M. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378067.lg24
Eng, G. K., Tambini, A., Hermiller, M. S., Recchia, N., Harvey, J. R., Iosifescu, D. V., Tobe, R. H., & Stern, E. R. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1587644 · Cited by 1
Qin, Y., Cai, L., Cheng, L., Xiang, L., & Hu, X. (2025) · Research Square · doi:10.21203/rs.3.rs-6655404/v1
Davis, R. A. (2022) · The Conversation · doi:10.64628/aai.9p9vtgdtj
Kim, H., Tyler, J., Wheaton, M. G., Park, S., Woo, C., Foa, E. B., & Simpson, H. B. (2025) · Psychological Medicine · doi:10.1017/s0033291725101906 · Cited by 1
“However, responses among patients are heterogenous (Simpson et al., 2006, 2008; Simpson, Foa et al., 2013, 2021). while some achieve remission, others havepartialresponses, andstillothersareleftwithimpairingresidualsymptoms.”
Self-citationPsychoanalysis, Psychotherapy, and Behavioral Sciences
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_6
Kwon, M., Park, M., Kim, M., Kang, J., Ahn, W., Chung, D., Choi, J.-S., & Jung, Y. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00937 · Cited by 1
Cognitive Behavioral Therapy With Exposure and Response Prevention for Obsessive-Compulsive Disorder
Ward, H. E., Moran-Meder, E., & McKay, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29009-1.00140-2
Nutraceuticals and obsessive-compulsive disorder therapy
Mohammadi, A. H., Amin, N., Tavousi, S. A., Mahabady, M. K., Aschner, M., & Mirzaei, H. (2026) · Advances in neurotoxicology · doi:10.1016/bs.ant.2026.03.001
Tochadse, M., Klawohn, J., Kaufmann, C., Grützmann, R., Riesel, A., Heinzel, S., Rane, R. P., da Silva, S. P., Wellan, S. A., Gijsen, S., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-64405-y
Remission and response rates in obsessive–compulsive disorder: Naturalistic study
Levy, D. M., Arush, O. B., Zemach, S., Juven‐Wetzler, A., & Zohar, J. (2026) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2026.152740
Gattuso, J. J., Bezcioglu, B., Hendey, J., Payet, J. M., Phelan, Z. J., Hale, M. W., Hannan, A. J., & Renoir, T. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03879-8 · Cited by 1
Söderholm, P., & Brander, G. (2013) · DiVA (Digitala Vetenskapliga Arkivet)
Metadata
- Authors
- Simpson, H. B., Huppert, J. D., Petkova, E., Foa, E. B., & Liebowitz, M. R.
- Affiliations
- New York State Psychiatric Institute (US)
- University of Pennsylvania (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-02-15
- Volume
- 67
- Issue
- 02
- Pages
- 269-276
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011811397
- Cited by
- 241
- References
- 0
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 8 · 2023: 7 · 2022: 14 · 2021: 21 · 2020: 8 · 2019: 17 · 2018: 12 · 2017: 12 · 2016: 13 · 2015: 15 · 2014: 11 · 2013: 15 · 2012: 15
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH045404, R01MH-45404, K23MH001907, MH01907, R01MH045436, R01MH-45436)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, treatment response, remission, exposure and response prevention, clomipramine, combination therapy, Yale-Brown Obsessive Compulsive Scale, comorbid depression, adults
- MeSH terms
- Adult, Ambulatory Care, Antidepressive Agents, Tricyclic, Clomipramine, Combined Modality Therapy, Female, Humans, Male, Terminology as Topic, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Psychometrics, Cognitive Behavioral Therapy, Treatment Outcome, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.